US20170042782A1 - Stabilized polyribonucleotide coding for an elastic fibrous protein - Google Patents

Stabilized polyribonucleotide coding for an elastic fibrous protein Download PDF

Info

Publication number
US20170042782A1
US20170042782A1 US14/868,259 US201514868259A US2017042782A1 US 20170042782 A1 US20170042782 A1 US 20170042782A1 US 201514868259 A US201514868259 A US 201514868259A US 2017042782 A1 US2017042782 A1 US 2017042782A1
Authority
US
United States
Prior art keywords
polyribonucleotide
triphosphate
elastin
seq
mrna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/868,259
Inventor
Hans-Peter Wendel
Timea Keller
Andrea Nolte
Meltem Avci-Adali
Tobias Walker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eberhard Karls Universitaet Tuebingen
Original Assignee
Eberhard Karls Universitaet Tuebingen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eberhard Karls Universitaet Tuebingen filed Critical Eberhard Karls Universitaet Tuebingen
Assigned to EBERHARD-KARLS-UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET reassignment EBERHARD-KARLS-UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: WALKER, TOBIAS, KELLER, Timea, AVCI-ADALI, Meltem, WENDEL, HANS-PETER, NOLTE, ANDREA
Publication of US20170042782A1 publication Critical patent/US20170042782A1/en
Priority to US17/494,751 priority Critical patent/US20220249346A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]

Definitions

  • the present invention relates to a polyribonucleotide, a cosmetic and pharmaceutical composition comprising said polyribonucleotide, and a medical product comprising said polyribonucleotide or said composition.
  • Elastic fibers are the largest structures of the extracellular matrix. They give elastic properties to the tissue.
  • the elastic fibers consist of two morphologically distinct components. The first and largest component of the mature fiber is the elastin.
  • the second component are the micro-fibrills which mainly consist of fibrillin and are associated with further proteins such as the micro-fibrills associated glycoproteins (MAGPs), fibulines, and the elastin-micro-fibrills-interface localized proteins (EMILIN).
  • MAGPs micro-fibrills associated glycoproteins
  • EMILIN elastin-micro-fibrills-interface localized proteins
  • LOX lysyl oxidase
  • Elastin and its soluble precursor tropoelastin belong to the major structural proteins of the body. It provides structure and support to the connective tissue and is responsible for the elasticity of arteries and the lung.
  • Elastin is encoded by the ELN gene. Mutations in the ELN gene may result in inherited disorders such as dermatochalasis, Williams-Beuren syndrome, and sub valvular innate aortic stenosis (SVAS).
  • SVAS sub valvular innate aortic stenosis
  • Arteriosclerotic blood vessels are subject to a loss of elastin which cannot be naturally compensated by cells involved in the regeneration. This is due to the fact that elastin-forming cells only synthesize and secrete new elastin up to a certain age and during the growth of the organism.
  • the protein is cross-linked in the extracellular space with each other and with other proteins of the connective tissue. Since elastin is particularly durable because of the cross-linking after having reached the full body height the need of an organism is fulfilled and the synthesis is almost ceased.
  • a polyribonucleotide encoding an elastic fibrous protein comprising a nucleotide sequence which comprises at least one chemical modification stabilizing said polyribonucleotide.
  • the inventors have surprisingly realized that a deficiency of the synthesis of elastic fibrous protein can be counteracted in a causal manner by providing the coding sequence to the cell in a form ready for a direct translation.
  • the polyribonucleotide according to the invention can be introduced into the cells to be regenerated and can induce the synthesis of elastic fibrous protein in situ.
  • the cells transfer the synthesized elastic fibrous protein into the natural path of the assembly of elastic fibers. This ensures not only the synthesis of the elastic fibrous protein but also the new synthesis of the elastic fibers. Neither the administration of elastic proteins as such nor of other proteins being involved in the genesis of elastic fibers could so far provide similar results.
  • IVT in vitro transcription
  • the inventors have realized that the synthesis of elastic fibrous protein in situ, that means in the cell, can compensate a deficiency, e.g. due to a mutation but also due to an age-related cease of the natural synthesis, in a targeted manner.
  • the polyribonucleotide is sufficiently stable to be translated by the cell-own machinery.
  • the polyribonucleotide according to the invention is sufficiently instable to only develop a temporary effect so that side effects can be largely avoided.
  • the immune response of an organism treated with the polynucleotide according to the invention is sufficiently smaller than by using a reference polyribonucleotide which is not chemically modified. This results in an additional increase in the therapeutic benefit of the polyribonucleotide according to the invention.
  • the elastic fibrous protein is selected from the group consisting of: elastin/tropoelastin, fibrillin, micro-fibrills associated glycoprotein (MAGP), fibuline, elastin-micro-fibrills-interface localized protein (EMILIN) and lysyl oxidase (LOX) and precursors thereof.
  • polyribonucleotide according to the invention is configured for the induction of the in situ synthesis of the most important elastic fibrous proteins.
  • elastic fibrous proteins preference is given to the human variants so that the use in humans is fostered.
  • polyribonucleotide is an mRNA.
  • polyribonucleotide is provided in a form which can immediately be used by the cell-own protein synthesis machinery.
  • This may include e.g. an in vitro transcribed mRNA (IVT-mRNA).
  • transcript variant 1 cDNA, NCBI data base NM_000501.2; SEQ ID No. 2
  • transcript variant 2 cDNA, NCBI data base NM_001081752.1; SEQ ID No. 3
  • transcript variant 3 cDNA; NCBI data base NM_001081753.1; SEQ ID No. 4
  • transcript variant 4 cDNA, NCBI data base NM_001081754.1; SEQ ID No. 5
  • transcript variant 5 cDNA, NCBI data base NM_001081755.1; SEQ ID No. 6).
  • the at least one chemical modification stabilizing said polyribonucleotide comprises a chemically modified nucleoside, preferably a modified uridine and/or cytidine.
  • the inventors have made use of the findings which are e.g. described by Kormann et al. (I.c.), namely that the mRNA after a chemical modification of the uridine ribonucleotides and/or cytidine ribonucleotides is not so easily recognized by structures of the immune system, such as the signal transduction mediating PRRs (“pattern recognition receptors”) or “Toll-like receptors”, thereby activating a significantly weakened immune response and obtaining a longer half-life period.
  • PRRs pattern recognition receptors
  • Toll-like receptors Toll-like receptors
  • nucleoside also encompasses a corresponding nucleotide comprising in comparison to the nucleoside additional phosphate residues.
  • the following chemically modified uridines or uridine ribonucleotides are of particular suitability: pseudouridine, 2-thiouridine, 5-methyluridine, 5-methyluridine-5′-triphosphate (m5U), 5-idouridine-5′-triphosphate (15U), 4-thiouridine-5′-triphosphate (S4U), 5-bromouridine-5′-triphosphate (Br5U), 2′-methyl-2′-deoxyuridine-5′-triphosphate (U2′m), 2′-amino-2′-deoxyuridine-5′-triphosphate (U2′NH2), 2′-azido-2′-deoxyuridine-5′-triphosphate (U2′N3), 2′-fluoro-2′-deoxyuridine-5′-triphosphate (U2′F) and combinations thereof.
  • pseudouridine 2-thiouridine
  • 5-methyluridine 5-methyluridine-5′-triphosphate
  • m5U 5-methyluridine-5′-triphosphate
  • 15U 5-i
  • Especially suitable chemically modified cytidines or cytidine ribonucleotides are: 5-methylcytidine, 3-methylcytidine, 2-thiocytidine, 2′-methyl-2′-deoxcytidin-5′-triphosphate (C2′m), 2′-amino-2′-deoxycytidine-5′-triphosphate (C2′NH2), 2′-fluoro-2′-deoxycytidine-5′-triphosphate (C2′F), 5-iodcytidine-5′-triphosphate (I5U), 5-bromocytidine-5′-triphosphate (Br5U), 2′-azido-2′-deoxycytidine-5′-triphosphate (C2′N3) and combinations thereof.
  • At least approx. 5%, further preferably at least approx. 7.5%, further preferably at least approx. 10%, and highly preferably at least 25% of the nucleosides or uridines and/or cytidines are modified.
  • nucleosides or uridines and/or cytidines can be modified the inventors have realized that a modification of up to approx. 25% of the nucleosides is sufficient for a stabilization of the polyribonucleotide according to the invention and reduction of the immune response. This has the advantage that the costs for the preparation of the polyribonucleotide according to the invention are significantly lower than for a 100% modification.
  • the chemical modification is selected from the group consisting of: 5 cap structure, preferably a 5′ guanine cap, poly (A) tail, a cap structure analog [anti-reverse cap analog (ARCA; 3′O-Me-m 7 G(5′)ppp(5′)ppp(5′)G)], a strengthening of the translation-initiation sequence at the start codon AUG, e.g. by the sequence (CCCCGC)aucGagAUG.
  • the polyribonucleotide according to the invention comprises the sequence of SEQ ID No. 1, where at least approx. 5%, further preferably at least approx. 7.5%, further preferably at least approx. 10%, and highly preferably at least approx. 25% of the uridines, and/or where at least approx. 5%, further preferably at least approx. 7.5%, further preferably at least approx. 10%, and highly preferably at least approx. 25% of the cytidines are chemically modified.
  • uridine (U) against pseudouridine or pseu-douridinetriphosphate ( ⁇ FUTP) and/or of cytidine (C) against 5-methylcytidine or 5-methylcytidinetriphosphate (mCTP) takes place.
  • the polyribonucleotide according to the invention preferably encodes an amino acid sequence which is selected from the group consisting of: SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, and SEQ ID No. 11.
  • polynucleotide according to the invention encodes one of the different isoforms of elastin (SEQ ID No. 7: isoform a, NCBI data base NP_00049.2; SEQ ID No. 8: isoform b, NCBI data base NP_001075221.1; SEQ ID No. 9: isoform c, NCBI data base NP_001075222.1; SEQ ID No. 10: isoform d, NCBI data base NP_001075223.1; SEQ ID No. 11: isoform e, NCBI data base NP_001075224.1).
  • the elastin isoforms comprise the effect which has been realized by the invention.
  • the polyribonucleotide is configured for the induction of the synthesis of elastic fibrous proteins, in particular in age-related loss of elasticity of the skin (wrinkle formation), promotion of the wound healing, for the treatment of a deficient synthesis of elastic fibrous proteins, or for the treatment of a disease selected from the group consisting of: arteriosclerosis, aortic stenosis, aortic aneurysm, pulmonary emphysema, dermatochalasis, Williams-Beuren syndrome, sub valvular innate aortic stenosis (SVAS).
  • a disease selected from the group consisting of: arteriosclerosis, aortic stenosis, aortic aneurysm, pulmonary emphysema, dermatochalasis, Williams-Beuren syndrome, sub valvular innate aortic stenosis (SVAS).
  • vaginal tissue can be treated, e.g. following a pregnancy, for the stimulation of the elastin synthesis and the recovery of the elasticity.
  • the polyribonucleotide according to the invention can be configured for dental applications, for example for the reconstruction and/or regeneration of soft or hard tissues of the periodontium. For this reason the polyribonucleotide according to the invention is preferably provided or configured for a transdermal application.
  • polyribonucleotide according to the invention is configured for the treatment of important diseases and phenomena which may result from a reduced synthesis of elastic fibrous protein.
  • the invention relates to the use of the polyribonucleotide according to the invention for the before-mentioned purposes.
  • the invention relates a method for the induction of the synthesis of elastic fibrous protein, in particular for the before-mentioned purposes, comprising the following steps: (1) provision of the polyribonucleotide according to the invention, if applicable, in a pharmaceutically/cosmetically acceptable formulation, and (2) administration of the polyribonucleotides in or to an organism.
  • the application of the polyribonucleotide in or to an organism may be effected via a topical application, for example onto the skin of the organism, preferably the human skin.
  • the polynucleotide may be a component of a dermatological dosage form such as a cream, lotion, ointment etc.
  • the administration can also be effected via appropriate dosage forms systemically, orally, intravenously, intraarterially, intramuscularly, intrathecally, subcutaneously, intraperitoneally, intracardially, intravitreally, or intraosseously etc.
  • transdermal administration of the polynucleotide according to the invention can be effected by means of micro needles, nanopatches, nanoparticles or by means of a gene gun.
  • active systems are appropriate which use iontophoresis.
  • a very small electrical current is transferred through the skin, which carries charged molecules.
  • An example for this is the iontophoresis LTS-TTS system of the company LTS Lohmann Therapie-Systeme AG, Andernach, Germany.
  • compositions comprising the polyribonucleotide according to the invention.
  • the composition according to the invention may be a cosmetical and/or pharmaceutical composition comprising a cosmetically or pharmaceutically acceptable formulation.
  • Cosmetically and pharmaceutically acceptable formulations are generally known in the state of the art. They are e.g. described in the assay of Kibbe et al., Handbook of Pharmaceutical Excipients, 5. Edition (2006), American Pharmaceutical Association .
  • the compositions may be configured as a mono preparation which contains the polyribonucleotide as the only active agent.
  • transfection tools such as liposomes, hydro gels, kationic polymers or peptides, salts, binding agents, solvents, dispersing agents and further compounds which are commonly used in connection with the formulation of cosmetics and pharmaceuticals.
  • composition can additionally comprise an immuno suppressive agent, preferably an interferon inhibitor.
  • This measure has the advantage that due to the chemical modification the already reduced immune response of a host treated with the polyribonucleotide according to the invention is further reduced.
  • the suppression of the immune response after the administration of a therapeutic mRNA by the use of the interferon inhibitor B18R which is suited for the use according to the invention, is documented in the state of the art, for example in Warren et al. (I.c.).
  • a medical product for example a patch or implant, which comprises the polyribonucleotide according to the invention or the composition according to the invention, respectively, or which is coated with the latter.
  • the implant may be a medical implant, preferably a stent including a coronary stent, or vascular implant, stent graft or a bone implant.
  • the implant allows a targeted treatment of arteriosclerotic blood vessels and/or local tissue areas, such as vaginal tissues, soft and hard tissues of the periodontium for the recovery of the elasticity.
  • Another subject-matter of the present invention is a wound dressing coated with the polyribonucleotide according to the invention.
  • Such a wound dressing can reduce the scaring and maintain the elasticity of the scar tissue by the induction of elastin synthesis.
  • FIG. 1 Plasmid preparations of four individually selected bacteria colonies were tested for correct insert by means of ELN-specific PCR. Detection of PCR products by means of agarose gel electrophoresis, 1.2% (120 V, 30 min). PCR cycles: denaturating 3 min, 94° C., 1. 40 sec, 94° C.-2. 1 min, 58° C.-3. 2.5 min, 72° C.; final amplification: 7 min, 72° C.;
  • FIG. 5 In vitro synthesized ELN protein on the basis of four different in vitro synthesized ELN-mRNAs and controls: 1, 2: marker; 3-6: protein synthesis with ELN-mRNAs from different in vitro transcription reactions (5: mRNA with modified nucleotides); 7: in vitro translation reaction without mRNA (negative control); 8: as in 7, but with addition of human, soluble elastin protein from Calbiochem (catalog number: 324751) after incubation time; 9: only water solved elastin protein from Calbiochem—according to data sheet the protein should run as a smear band between 5 and 60 kDa. Native elastin protein is detected by means of the used antibody at a level of 50 kDa.
  • FIG. 6 Detection of the elastin expression by measuring the amount of tropoelastin in EA.hy926 cells after transfection at three successive days with IVT-ELN-mRNA; they contained different fractions of modified nucleic acids (mCTP/ ⁇ FUTP) and Lipofectamin2000. RNA or Lipofectamin2000 alone were used as negative controls.
  • FIG. 7 Detection of the elastin expression in the supernatant of the EA.hy926 cells after transfection with 100% modified (mCTP/ ⁇ FUTP) IVT-ELN-mRNA by means of dot-blot assays; M: only cell culture medium, M+L: cell culture medium plus transfection reagent.
  • FIG. 8 Immune activation of EA.hy926 cells after the transfection of IVT-ELN-mRNA; the expressions were normalized to the housekeeping gene GAPDH. The negative controls were set to 1.
  • FIG. 9 Detection of the reporter gene expression: microscopic images of “stented” vessels, focus on the border between stent and tissue.
  • Lower picture images with FIDSAM and contrast correction.
  • FIG. 10 Detection of the Luciferase expression in pig skin after transfection with Luciferase mRNA
  • the Luciferase encoding, T7-promoter containing plasmid, pCMV-GLuc-1 used as a reporter gene was purchased from Nanolight Technology, Inc. and cloned into Qiagen EZ competent E. coli from the Qiagen PCT cloning kit.
  • the plasmids contain sites for sequencing with primers such as the M13 forward and reverse primers, and promoter regions for polymerases, such as Sp6 and T7. These sequences can be found 5 or 3′ to the inserted sequence of interest, respectively. Additionally, the insert region is flanked by short recognition sequences for specific restriction enzymes.
  • the plasmids were isolated with the Qiagen Plasmid Maxi kit (Qiagen).
  • Insert-specific primers were designed with a free primer designing tool from NCBI and produced by Eurofins MWG Operon.
  • the plasmid inserts were verified by PCR with the insert-specific primer pairs ( FIG. 1 ), and the following cycling parameters were used: denature 3 min at 94° C.; 1. 40 sec at 94° C.; 2. 1 min at 58° C.; 3. 2.5 min at 72° C.; repeat steps 1-3, 28 ⁇ ; final amplification 7 min, 72° C.
  • plasmid inserts were sequenced completely through the company GATC Biotech with self-designed insert-specific primers and with M13-forward and reverse primers. The sequence assembly was done with the DNA-baser program.
  • IVT in vitro transcription
  • plasmids were linearized downstream of the gene of interest with the Fast Digest Enzyme System (Fermentas/Thermo Scientific) and purified with the MiniElute PCR clean up kit (Qiagen). Test digests were performed prior to the experiment ( FIG. 2 ).
  • the in vitro transcription was performed according to the manufacturer's instructions with MEGAscript Sp6 kit. For each 40 ⁇ L IVT reaction 1 ⁇ g of linearized template was used. To optimize the stability and cytocompatibility of IVT-mRNAs in the reactions different ratios of the nucleic acid triphosphates 5-methylcytidine and pseudouridine (TriLink Biotechnologies) were combined with standard nucleotides from the kit.
  • the reactions were incubated for 3.5 hours at 37° C. and treated with DNase I from the kit at the end of the incubation period in compliance with the instructions of the manufacturer, in order to eliminate the template DNA.
  • the mRNA was purified with the RNeasy mini kit (Qiagen). The detection of the elastin mRNA was made by denaturating agarose gel electrophoresis ( FIG. 3 ). The concentrations of mRNAs were measured by means of BioPhotometer6131 (Eppendorf).
  • the quality of the in vitro transcribed mRNA was determined indirectly by in vitro translation with the Retic Lysate kit (Ambion), following luminescence measurement for the Luciferase or western blot analysis for elastin.
  • the in vitro translation reactions were set up according to the instructions of the manufacturer.
  • the lung carcinoma cell lines A549 and SK-MES were used for the first trials.
  • the endothelial cell/A549-hybridoma cell line EA-hy926 was used to establish effective transfection methods for endothelial cells and tissues.
  • mRNA transfections were performed by using the transfection reagent Lipofectamine2000 (Invitrogen/Life Technologies).
  • the medium for transfections was OptiMEM (Gibco/Life Technologies).
  • the negative controls throughout all experiments were OptiMEM with equal amounts of Lipofectamine2000 used for mRNA transfections or mRNA without transfection reagent in OptiMEM.
  • the cells were plated with a density of 500,000 cells per well in 6-well plates one day prior to the experiments.
  • the transfection was made with 5 or 10 ⁇ g of elastin mRNA and 3.3 ⁇ L of transfection reagent per well diluted in OptiMEM, based on the indications of the manufacturer.
  • the medium with the mRNA transfection complexes was added to the cells and the plates were incubated for 4 hours under cell culture conditions. Afterwards, 2 ⁇ 3 of the transfection mixes were replaced with fresh culture medium and the cells were incubated overnight. This transfection method was repeated for the following 2 days. At the third day the transfection complexes were completely replaced with fresh cell culture medium.
  • the first assessment of the Luciferase expression was performed 5 hours after the transfection and then following every day until the expression declined.
  • For luminescence measurements, representing the Luciferase expression 20 ⁇ L medium was taken from each well 6/24/48/72 hours and 5/10/25 days after transfection, with medium change after each sample taking.
  • FIG. 4 shows the measured luminescence relating to the Luciferase expression in the medium of IVT-mRNA transfected EA.hy926 cells.
  • the proteins from the in vitro translation reactions were separated on a 8% SDS-PAGE and blotted on a nitrocellulose membrane for the immunodetection.
  • the primary antibody was a rabbit polyclonal ELN antibody (central region) from Abgent and the secondary antibody was a goat anti-rabbit IgG (whole molecule) Alkaline Phosphatase Conjugate from Sigma-Aldrich.
  • the elastin protein was revealed by precipitation of the indigo dye resulting from NBT/BCIP reaction with alkaline phosphatase ( FIG. 5 ).
  • FIG. 6 shows the amount of tropoelastin isolated 24 hours after the last transfection with elastin-IVT-mRNAs, which contained various parts of modified nucleic acids.
  • the cells with elastin-mRNA-incubation show a significantly stronger staining than the cells without mRNA-transfection (M, M+L).
  • the EA.hy926-cells without elastin-mRNA synthesize low amounts of elastin, however by the elastin-mRNA-transfection the elastin synthesis is significantly increased.
  • Transfections for the analysis of cytokines and other markers of the immune activation were performed according to the mRNA-transfections described above. Additionally, the immunostimulant polyinosinic/polycytidylic acid (Sigma-Aldrich) was transfected at 100 ng/well as a positive control for cytokine activation. The cells were incubated with the transfection mix under cell culture conditions and the medium was replaced after 3 hours.
  • RNA-concentration was measured and 40 ng of each sample was used for cDNA-synthesis with iScript cDNA-synthesis kit (Biorad).
  • the generated cDNA was used diluted in (qRT)-PCR reactions with the iQ SYBR Green Supermix (Biorad) in triplicates for each sample, combined with a specific primer pair for IFN- ⁇ , IFN- ⁇ , IL-1 B, IL-12, IL-6, IL-8, TNF- ⁇ and a GAPDH-specific primer pair.
  • BMS coronary stents 3 ⁇ 20 mm of Qualimed (Winsen, Germany) were dip-coated, in an emulsion of 70 ⁇ g in vitro transcribed eGFP-mRNA complexed with 20 ⁇ L of Lipofectamin2000 in nuclease free water and 150 ⁇ g of polyactic-co-glycolic acid RESOMER® RG 502 H (Sigma Aldrich) solved in ethyl acetate.
  • the stents were implanted via a balloon catheter (3 mm) into the left and right coronary arteries of each pig and expanded. The location of the stents was displayed with help of an X-ray apparatus (C-Bogen) and radiopaque material. An overstretching of the arteries was2-ed intentionally. After the implantation, the animals received heparin and clopidogrel to prevent postoperative thromboses.
  • the stents were embedded in methylmetacrylate based embedding system Technovit® 9100 from HeraeusKulzer (Wehrheim, Germany), and analyzed by fluorescence intensity decay shape analysis microscopy FIDSAM (fluorescence intensity decay shape analysis microscopy) at the Institute of Analytical Chemistry of the University of Tubingen.
  • FIDSAM fluorescence intensity decay shape analysis microscopy
  • FIG. 9 There the part of fluorescent tissue visible after subtraction of the autofluorescence is shown. This fluorescence is only due to the induced eGFP expression and therefore the evidence for efficient uptake and translation of the IVT-mRNA encoding eGFP by cells surrounding the stent material.
  • a pig skin model was established to detect the synthesis of the mRNA-induced elastin in the skin.
  • 2.5 ⁇ g of Luciferase m RNA/Lipofectamin 2000 complexes were injected into the skin.
  • the skin was chopped after 24 h and for isolating the Luciferase the cells were lysed.
  • the result is shown in FIG. 10 .
  • the Luciferase Assay the successful transfection of the cells with Luciferase mRNA was demonstrated.
  • SEQ ID No. 1 Nucleotide sequence of the IVT-elastin-mRNA (as used in the embodiments)
  • SEQ ID No. 2 Nucleotide sequence of the cDNA, derived from the mRNA of the human elastin, transcript variant 1 (NM_000501.2)
  • SEQ ID No. 3 Nucleotide sequence of the cDNA, derived from the mRNA of the human elastin, transcript variant 2 (NM_001081752.1)
  • SEQ ID No. 4 Nucleotide sequence of the cDNA, derived from the mRNA of the human elastin, transcript variant 3 (NM_001081753.1)
  • SEQ ID No. 5 Nucleotide sequence of the cDNA, derived from the mRNA of the human elastin, transcript variant 4 (NM_001081754.1)
  • SEQ ID No. 6 Nucleotide sequence of the cDNA, derived from the mRNA of the human elastin, transcript variant 5 (NM_001081755.1)
  • SEQ ID No. 7 Amino acid sequence of the elastin isoform a [ homo sapiens] (NP_00049.2)
  • SEQ ID No. 8 Amino acid sequence of the elastin isoform b [ homo sapiens] (NP_001075221.1)
  • SEQ ID No. 9 Amino acid sequence of the elastin isoform c [ homo sapiens] (NP_001075222.1)
  • SEQ ID No. 10 Amino acid sequence of the elastin isoform d [ homo sapiens] (NP_001075223.1)
  • SEQ ID No. 11 Amino acid sequence of the elastin isoform e [ homo sapiens] (NP_001075224.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)

Abstract

The invention relates to a polyribonucleotide, a cosmetic and pharmaceutical compound that has the polyribonucleotide and a medicinal product that has the polyribonucleotide and the compound.

Description

    CROSS-REFERENCES TO RELATED APPLICATIONS
  • This application is a continuation of copending international patent application PCT/EP2014/056233 field on 27 Mar. 2014 and designating the U.S., which has been published in German, and claims priority from the German patent application DE 10 2013 005 361.7, filed on 28 Mar. 2013. The entire contents of these priority applications are incorporated herein by reference.
    • REFERENCE TO A SEQUENCE LISTING
  • This application contains references to nucleic acid sequences and/or amino acid sequences which have been submitted concurrently herewith as the sequence listing text file “5402P503_ST25.txt”, file size 60 KiloBytes (KB), created on 23 Sep. 2015. The afore-mentioned sequence listing is hereby incorporated by reference in its entirety pursuant to 37 C.F.R. §1.52(e)(5).
    • FIELD
  • The present invention relates to a polyribonucleotide, a cosmetic and pharmaceutical composition comprising said polyribonucleotide, and a medical product comprising said polyribonucleotide or said composition.
    • BACKGROUND
  • Elastic fibers are the largest structures of the extracellular matrix. They give elastic properties to the tissue. The elastic fibers consist of two morphologically distinct components. The first and largest component of the mature fiber is the elastin. The second component are the micro-fibrills which mainly consist of fibrillin and are associated with further proteins such as the micro-fibrills associated glycoproteins (MAGPs), fibulines, and the elastin-micro-fibrills-interface localized proteins (EMILIN). The lysyl oxidase (LOX) is involved in the cross-linking of the elastic fibers.
  • Elastin and its soluble precursor tropoelastin belong to the major structural proteins of the body. It provides structure and support to the connective tissue and is responsible for the elasticity of arteries and the lung.
  • Elastin is encoded by the ELN gene. Mutations in the ELN gene may result in inherited disorders such as dermatochalasis, Williams-Beuren syndrome, and sub valvular innate aortic stenosis (SVAS).
  • Arteriosclerotic blood vessels are subject to a loss of elastin which cannot be naturally compensated by cells involved in the regeneration. This is due to the fact that elastin-forming cells only synthesize and secrete new elastin up to a certain age and during the growth of the organism. In the following the protein is cross-linked in the extracellular space with each other and with other proteins of the connective tissue. Since elastin is particularly durable because of the cross-linking after having reached the full body height the need of an organism is fulfilled and the synthesis is almost ceased.
  • Because of the reduced synthesis of elastin in the old age the skin loses its flexibility and begins to develop wrinkles.
  • There are no satisfying or even causal therapies of a deficient synthesis of elastic fibrous protein, in particular elastin.
  • Hirano et al. (2007), Functional rescue of elastin insufficiency in mice by the human elastin gene: implications for mouse models of human disease, Circulation Research 101: 523-531, describe the introduction of human elastin by means of a DNA plasmid into mice oocytes. However, this approach is not suitable for a therapeutic application in humans.
    • SUMMARY
  • Against this background it is an object of the present invention to provide a substance by means of which the problems mentioned at the outset can be solved. In particular, such a substance should be provided which can counteract a lack of elastic fibers or elastic fibrous protein, respectively, and which can stimulate the synthesis of elastic fibers or elastic fibrous protein.
  • This object is achieved by the provision of a polyribonucleotide encoding an elastic fibrous protein comprising a nucleotide sequence which comprises at least one chemical modification stabilizing said polyribonucleotide.
  • The inventors have surprisingly realized that a deficiency of the synthesis of elastic fibrous protein can be counteracted in a causal manner by providing the coding sequence to the cell in a form ready for a direct translation. The polyribonucleotide according to the invention can be introduced into the cells to be regenerated and can induce the synthesis of elastic fibrous protein in situ. The cells transfer the synthesized elastic fibrous protein into the natural path of the assembly of elastic fibers. This ensures not only the synthesis of the elastic fibrous protein but also the new synthesis of the elastic fibers. Neither the administration of elastic proteins as such nor of other proteins being involved in the genesis of elastic fibers could so far provide similar results.
  • The stabilization of polyribonucleotides, for example of mRNA, is extensively described in the state of the art. It is referred to the following publications: US 2009/0093433, WO 2011/012316, WO 2012/135805, WO 2012/045082, WO 2012/019168, WO 2012/045075, WO 2012/158736. Furthermore, the stabilization of mRNA by chemical modification of ribonucleotides is described in the publications of Warren et al. (2010), High efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA, Cell Stem Cell 7, p. 618 to 630, and Kormann et al. (2011), Expression of therapeutic proteins after delivery of chemically modified mRNA in mice, Nature Biotechnology, Vol. 29, No. 2, p. 154 to 159, Mandal and Rossi (2013), Reprogramming human fibroblast to pluripotency using modified mRNA, Nature Protocols, Vol. 8, No. 3, p. 568 to 582.
  • Methods for the synthesis of polyribonucleotides, such as mRNA, are extensive described in the state of the art. One of the suitable methods is the in vitro transcription (IVT). The resulting mRNA is also referred to as IVT-mRNA.
  • The inventors have realized that the synthesis of elastic fibrous protein in situ, that means in the cell, can compensate a deficiency, e.g. due to a mutation but also due to an age-related cease of the natural synthesis, in a targeted manner.
  • Because of the chemical modification the polyribonucleotide is sufficiently stable to be translated by the cell-own machinery. However, the polyribonucleotide according to the invention is sufficiently instable to only develop a temporary effect so that side effects can be largely avoided.
  • As the inventors were able to show, the immune response of an organism treated with the polynucleotide according to the invention is sufficiently smaller than by using a reference polyribonucleotide which is not chemically modified. This results in an additional increase in the therapeutic benefit of the polyribonucleotide according to the invention.
  • The object underlying the invention is herewith completely solved.
  • According to the invention it is preferred if the elastic fibrous protein is selected from the group consisting of: elastin/tropoelastin, fibrillin, micro-fibrills associated glycoprotein (MAGP), fibuline, elastin-micro-fibrills-interface localized protein (EMILIN) and lysyl oxidase (LOX) and precursors thereof.
  • This measure has the advantage that the polyribonucleotide according to the invention is configured for the induction of the in situ synthesis of the most important elastic fibrous proteins. For the mentioned elastic fibrous proteins preference is given to the human variants so that the use in humans is fostered.
  • In an embodiment the polyribonucleotide is an mRNA.
  • This measure has the advantage that the polyribonucleotide is provided in a form which can immediately be used by the cell-own protein synthesis machinery. This may include e.g. an in vitro transcribed mRNA (IVT-mRNA).
  • According to the invention one of the following mRNA stabilized by chemical modification is preferred: human elastin, transcript variant 1 (cDNA, NCBI data base NM_000501.2; SEQ ID No. 2), transcript variant 2 (cDNA, NCBI data base NM_001081752.1; SEQ ID No. 3), transcript variant 3 (cDNA; NCBI data base NM_001081753.1; SEQ ID No. 4), transcript variant 4 (cDNA, NCBI data base NM_001081754.1; SEQ ID No. 5), transcript variant 5 (cDNA, NCBI data base NM_001081755.1; SEQ ID No. 6).
  • In another embodiment the at least one chemical modification stabilizing said polyribonucleotide comprises a chemically modified nucleoside, preferably a modified uridine and/or cytidine.
  • By this measure the inventors have made use of the findings which are e.g. described by Kormann et al. (I.c.), namely that the mRNA after a chemical modification of the uridine ribonucleotides and/or cytidine ribonucleotides is not so easily recognized by structures of the immune system, such as the signal transduction mediating PRRs (“pattern recognition receptors”) or “Toll-like receptors”, thereby activating a significantly weakened immune response and obtaining a longer half-life period.
  • According to the invention a nucleoside also encompasses a corresponding nucleotide comprising in comparison to the nucleoside additional phosphate residues.
  • The following chemically modified uridines or uridine ribonucleotides are of particular suitability: pseudouridine, 2-thiouridine, 5-methyluridine, 5-methyluridine-5′-triphosphate (m5U), 5-idouridine-5′-triphosphate (15U), 4-thiouridine-5′-triphosphate (S4U), 5-bromouridine-5′-triphosphate (Br5U), 2′-methyl-2′-deoxyuridine-5′-triphosphate (U2′m), 2′-amino-2′-deoxyuridine-5′-triphosphate (U2′NH2), 2′-azido-2′-deoxyuridine-5′-triphosphate (U2′N3), 2′-fluoro-2′-deoxyuridine-5′-triphosphate (U2′F) and combinations thereof.
  • Especially suitable chemically modified cytidines or cytidine ribonucleotides are: 5-methylcytidine, 3-methylcytidine, 2-thiocytidine, 2′-methyl-2′-deoxcytidin-5′-triphosphate (C2′m), 2′-amino-2′-deoxycytidine-5′-triphosphate (C2′NH2), 2′-fluoro-2′-deoxycytidine-5′-triphosphate (C2′F), 5-iodcytidine-5′-triphosphate (I5U), 5-bromocytidine-5′-triphosphate (Br5U), 2′-azido-2′-deoxycytidine-5′-triphosphate (C2′N3) and combinations thereof.
  • According to the invention at least approx. 5%, further preferably at least approx. 7.5%, further preferably at least approx. 10%, and highly preferably at least 25% of the nucleosides or uridines and/or cytidines are modified.
  • Even though at least approx. 50% or approx. 100% of the nucleosides or uridines and/or cytidines can be modified the inventors have realized that a modification of up to approx. 25% of the nucleosides is sufficient for a stabilization of the polyribonucleotide according to the invention and reduction of the immune response. This has the advantage that the costs for the preparation of the polyribonucleotide according to the invention are significantly lower than for a 100% modification.
  • In another embodiment the chemical modification is selected from the group consisting of: 5 cap structure, preferably a 5′ guanine cap, poly (A) tail, a cap structure analog [anti-reverse cap analog (ARCA; 3′O-Me-m7G(5′)ppp(5′)ppp(5′)G)], a strengthening of the translation-initiation sequence at the start codon AUG, e.g. by the sequence (CCCCGC)aucGagAUG.
  • By this measure an additional stabilization of the polyribonucleotide according to the invention is achieved in a beneficial manner.
  • In another embodiment the polyribonucleotide according to the invention comprises the sequence of SEQ ID No. 1, where at least approx. 5%, further preferably at least approx. 7.5%, further preferably at least approx. 10%, and highly preferably at least approx. 25% of the uridines, and/or where at least approx. 5%, further preferably at least approx. 7.5%, further preferably at least approx. 10%, and highly preferably at least approx. 25% of the cytidines are chemically modified.
  • As mentioned above it is true that also at least approx. 50% or at least approx. 100% of the nucleosides can be modified, however an approx. 25% modification is sufficient.
  • The definition of “chemically modified” as set forth above applies here correspondingly. Preferably an exchange of uridine (U) against pseudouridine or pseu-douridinetriphosphate (ΨFUTP) and/or of cytidine (C) against 5-methylcytidine or 5-methylcytidinetriphosphate (mCTP) takes place.
  • The polyribonucleotide according to the invention preferably encodes an amino acid sequence which is selected from the group consisting of: SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, and SEQ ID No. 11.
  • This measure has the advantage that the polynucleotide according to the invention encodes one of the different isoforms of elastin (SEQ ID No. 7: isoform a, NCBI data base NP_00049.2; SEQ ID No. 8: isoform b, NCBI data base NP_001075221.1; SEQ ID No. 9: isoform c, NCBI data base NP_001075222.1; SEQ ID No. 10: isoform d, NCBI data base NP_001075223.1; SEQ ID No. 11: isoform e, NCBI data base NP_001075224.1). The elastin isoforms comprise the effect which has been realized by the invention.
  • According to the invention it is preferred if the polyribonucleotide is configured for the induction of the synthesis of elastic fibrous proteins, in particular in age-related loss of elasticity of the skin (wrinkle formation), promotion of the wound healing, for the treatment of a deficient synthesis of elastic fibrous proteins, or for the treatment of a disease selected from the group consisting of: arteriosclerosis, aortic stenosis, aortic aneurysm, pulmonary emphysema, dermatochalasis, Williams-Beuren syndrome, sub valvular innate aortic stenosis (SVAS).
  • In addition, by means of the polyribonucleotide according to the invention the vaginal tissue can be treated, e.g. following a pregnancy, for the stimulation of the elastin synthesis and the recovery of the elasticity.
  • Furthermore, the polyribonucleotide according to the invention can be configured for dental applications, for example for the reconstruction and/or regeneration of soft or hard tissues of the periodontium. For this reason the polyribonucleotide according to the invention is preferably provided or configured for a transdermal application.
  • These measures have the advantage that the polyribonucleotide according to the invention is configured for the treatment of important diseases and phenomena which may result from a reduced synthesis of elastic fibrous protein.
  • For this reason the invention relates to the use of the polyribonucleotide according to the invention for the before-mentioned purposes.
  • Furthermore, the invention relates a method for the induction of the synthesis of elastic fibrous protein, in particular for the before-mentioned purposes, comprising the following steps: (1) provision of the polyribonucleotide according to the invention, if applicable, in a pharmaceutically/cosmetically acceptable formulation, and (2) administration of the polyribonucleotides in or to an organism.
  • The application of the polyribonucleotide in or to an organism may be effected via a topical application, for example onto the skin of the organism, preferably the human skin. For this purpose the polynucleotide may be a component of a dermatological dosage form such as a cream, lotion, ointment etc. However, the administration can also be effected via appropriate dosage forms systemically, orally, intravenously, intraarterially, intramuscularly, intrathecally, subcutaneously, intraperitoneally, intracardially, intravitreally, or intraosseously etc.
  • The transdermal administration of the polynucleotide according to the invention can be effected by means of micro needles, nanopatches, nanoparticles or by means of a gene gun. In addition, active systems are appropriate which use iontophoresis. Here a very small electrical current is transferred through the skin, which carries charged molecules. An example for this is the iontophoresis LTS-TTS system of the company LTS Lohmann Therapie-Systeme AG, Andernach, Germany.
  • Against this background a further object of the present invention is a composition comprising the polyribonucleotide according to the invention. The composition according to the invention may be a cosmetical and/or pharmaceutical composition comprising a cosmetically or pharmaceutically acceptable formulation. Cosmetically and pharmaceutically acceptable formulations are generally known in the state of the art. They are e.g. described in the assay of Kibbe et al., Handbook of Pharmaceutical Excipients, 5. Edition (2006), American Pharmaceutical Association. The compositions may be configured as a mono preparation which contains the polyribonucleotide as the only active agent. However, they may contain additives and, if applicable, further active agents and excipients which are beneficial for the uses according to the invention, including transfection tools such as liposomes, hydro gels, kationic polymers or peptides, salts, binding agents, solvents, dispersing agents and further compounds which are commonly used in connection with the formulation of cosmetics and pharmaceuticals.
  • In another embodiment of the invention the composition can additionally comprise an immuno suppressive agent, preferably an interferon inhibitor.
  • This measure has the advantage that due to the chemical modification the already reduced immune response of a host treated with the polyribonucleotide according to the invention is further reduced. The suppression of the immune response after the administration of a therapeutic mRNA by the use of the interferon inhibitor B18R which is suited for the use according to the invention, is documented in the state of the art, for example in Warren et al. (I.c.).
  • Another subject-matter of the present invention is a medical product, for example a patch or implant, which comprises the polyribonucleotide according to the invention or the composition according to the invention, respectively, or which is coated with the latter. The implant may be a medical implant, preferably a stent including a coronary stent, or vascular implant, stent graft or a bone implant.
  • The implant allows a targeted treatment of arteriosclerotic blood vessels and/or local tissue areas, such as vaginal tissues, soft and hard tissues of the periodontium for the recovery of the elasticity.
  • Another subject-matter of the present invention is a wound dressing coated with the polyribonucleotide according to the invention.
  • Such a wound dressing can reduce the scaring and maintain the elasticity of the scar tissue by the induction of elastin synthesis.
  • It is to be understood that the features of the invention mentioned above and those yet to be explained below can be used not only in the respective combination indicated, but also in other combinations or in isolation, without leaving the scope of the present invention.
  • The present invention is now further explained by means of embodiments which result in further characteristics and advantages of the invention. The examples are purely illustrative and do not restrict the scope of the invention. Reference is made to the enclosed figures.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1: Plasmid preparations of four individually selected bacteria colonies were tested for correct insert by means of ELN-specific PCR. Detection of PCR products by means of agarose gel electrophoresis, 1.2% (120 V, 30 min). PCR cycles: denaturating 3 min, 94° C., 1. 40 sec, 94° C.-2. 1 min, 58° C.-3. 2.5 min, 72° C.; final amplification: 7 min, 72° C.;
  • FIG. 2: Distinctively cutting restriction enzymes were determined by means of test digests of the plasmid and analysis in the following on a 1% agarose gel (120 V, 40 min). Bands: 1-marker/DNA ladder, 2-5: test digest of the plasmid with different downstream (3′) cutting restriction enzymes: 2: Not I, 3: Xba I, 4: Bfa I, 5: Xho I, 6: digest with downstream (5′) cutting enzyme, EcoRI, 7-10: downstream cutting enzymes were combined with Ecor I (double digest), order as 2-5. kb=kilobases;
  • FIG. 3: In vitro synthesized ELN-mRNA in denaturating agarose gel electrophoresis 1% (16% formaldehyde, 100 V, 45 min). 1: IVT reaction after 3 h incubation; 2: IVT reaction with polyadenylating mix and 25 min incubation; 3: as in 2, after 45 min; 4: marker; 5-6: purified, polyadenylated ELN-mRNAs; 5, 6: with Ambion MEGAclear Kit (catalog number AM1908); 7: with Qiagen RNeasy Midi Kit, double RNA amount (catalog number: 75142);
  • FIG. 4: Detection of reporter gene expression: detection of the Luciferase expression after transfection of IVT-Luciferase-mRNA into EA.hy926. hpt=hours post transfection; dpt=days post transfection;
  • FIG. 5: In vitro synthesized ELN protein on the basis of four different in vitro synthesized ELN-mRNAs and controls: 1, 2: marker; 3-6: protein synthesis with ELN-mRNAs from different in vitro transcription reactions (5: mRNA with modified nucleotides); 7: in vitro translation reaction without mRNA (negative control); 8: as in 7, but with addition of human, soluble elastin protein from Calbiochem (catalog number: 324751) after incubation time; 9: only water solved elastin protein from Calbiochem—according to data sheet the protein should run as a smear band between 5 and 60 kDa. Native elastin protein is detected by means of the used antibody at a level of 50 kDa.
  • FIG. 6: Detection of the elastin expression by measuring the amount of tropoelastin in EA.hy926 cells after transfection at three successive days with IVT-ELN-mRNA; they contained different fractions of modified nucleic acids (mCTP/ΨFUTP) and Lipofectamin2000. RNA or Lipofectamin2000 alone were used as negative controls.
  • FIG. 7: Detection of the elastin expression in the supernatant of the EA.hy926 cells after transfection with 100% modified (mCTP/ΨFUTP) IVT-ELN-mRNA by means of dot-blot assays; M: only cell culture medium, M+L: cell culture medium plus transfection reagent.
  • FIG. 8: Immune activation of EA.hy926 cells after the transfection of IVT-ELN-mRNA; the expressions were normalized to the housekeeping gene GAPDH. The negative controls were set to 1.
  • FIG. 9: Detection of the reporter gene expression: microscopic images of “stented” vessels, focus on the border between stent and tissue. A, B: negative controls (uncoated stents). C-E: eGPF-mRNA-coated stents. The size of the images corresponds to an area of 30×30 μm. Upper picture: original image. Lower picture: images with FIDSAM and contrast correction.
  • FIG. 10: Detection of the Luciferase expression in pig skin after transfection with Luciferase mRNA
    •  EXAMPLES 1. Plasmids Constructs for the RNA Synthesis
  • An elastin, transcript variant 1 encoding (SEQ ID No. 2) Sp6-promoter containing plasmid, pCMV-Sp6_ELN, cloned into E. coli, was purchased from Thermo Scientific.
  • The Luciferase encoding, T7-promoter containing plasmid, pCMV-GLuc-1 used as a reporter gene, was purchased from Nanolight Technology, Inc. and cloned into Qiagen EZ competent E. coli from the Qiagen PCT cloning kit.
  • The plasmids contain sites for sequencing with primers such as the M13 forward and reverse primers, and promoter regions for polymerases, such as Sp6 and T7. These sequences can be found 5 or 3′ to the inserted sequence of interest, respectively. Additionally, the insert region is flanked by short recognition sequences for specific restriction enzymes.
    • 2. Verification of Plasmid Inserts
  • The plasmids were isolated with the Qiagen Plasmid Maxi kit (Qiagen).
  • Insert-specific primers were designed with a free primer designing tool from NCBI and produced by Eurofins MWG Operon. The plasmid inserts were verified by PCR with the insert-specific primer pairs (FIG. 1), and the following cycling parameters were used: denature 3 min at 94° C.; 1. 40 sec at 94° C.; 2. 1 min at 58° C.; 3. 2.5 min at 72° C.; repeat steps 1-3, 28×; final amplification 7 min, 72° C.
  • Additionally, plasmid inserts were sequenced completely through the company GATC Biotech with self-designed insert-specific primers and with M13-forward and reverse primers. The sequence assembly was done with the DNA-baser program.
    • 3. In Vitro Synthesis of ELN-mRNA with Different Amounts of Modified Nucleic Acids
  • For the in vitro transcription (IVT) plasmids were linearized downstream of the gene of interest with the Fast Digest Enzyme System (Fermentas/Thermo Scientific) and purified with the MiniElute PCR clean up kit (Qiagen). Test digests were performed prior to the experiment (FIG. 2).
  • The in vitro transcription was performed according to the manufacturer's instructions with MEGAscript Sp6 kit. For each 40 μL IVT reaction 1 μg of linearized template was used. To optimize the stability and cytocompatibility of IVT-mRNAs in the reactions different ratios of the nucleic acid triphosphates 5-methylcytidine and pseudouridine (TriLink Biotechnologies) were combined with standard nucleotides from the kit.
  • TABLE 1
    nucleotide mixtures in the IVT reactions with different amounts
    of 5-methylcytidine and pseudouridine
    5-methyl-
    CTP citidine UTP Pseudouridine
    25% modification 5.25 mM 1.75 mM 5.25 mM 1.75 mM
    50% modification  3.5 mM  3.5 mM  3.5 mM  3.5 mM
    100% modification  —   7 mM —   7 mM
  • In each IVT reaction 6 mM ATP, 3 mM GTP (from the kit) and 2 mM 3′-O-Me-m7G(5′)ppp(5′)G (anti-reverse cap-analog from New England Biolabs) were used. Further components were added as indicated in the manual of the kit.
  • The reactions were incubated for 3.5 hours at 37° C. and treated with DNase I from the kit at the end of the incubation period in compliance with the instructions of the manufacturer, in order to eliminate the template DNA.
  • The polyadenylation was made with the PolyA Tailing kit (Ambion) according to the instructions of the manufacturer.
  • The mRNA was purified with the RNeasy mini kit (Qiagen). The detection of the elastin mRNA was made by denaturating agarose gel electrophoresis (FIG. 3). The concentrations of mRNAs were measured by means of BioPhotometer6131 (Eppendorf).
    • 4. In Vitro Translation of In Vitro Transcribed mRNAs
  • The quality of the in vitro transcribed mRNA was determined indirectly by in vitro translation with the Retic Lysate kit (Ambion), following luminescence measurement for the Luciferase or western blot analysis for elastin. The in vitro translation reactions were set up according to the instructions of the manufacturer.
    • 5. Cell Lines and Chemicals Used for the Transfection of IVT-mRNAs
  • The lung carcinoma cell lines A549 and SK-MES were used for the first trials. The endothelial cell/A549-hybridoma cell line EA-hy926 was used to establish effective transfection methods for endothelial cells and tissues.
  • All mRNA transfections were performed by using the transfection reagent Lipofectamine2000 (Invitrogen/Life Technologies). The medium for transfections was OptiMEM (Gibco/Life Technologies). The negative controls throughout all experiments were OptiMEM with equal amounts of Lipofectamine2000 used for mRNA transfections or mRNA without transfection reagent in OptiMEM.
    • 6. Transfection of IVT-mRNAs in Cell Culture
  • For the transfections with elastin mRNA the cells were plated with a density of 500,000 cells per well in 6-well plates one day prior to the experiments.
  • The transfection was made with 5 or 10 μg of elastin mRNA and 3.3 μL of transfection reagent per well diluted in OptiMEM, based on the indications of the manufacturer.
  • The medium with the mRNA transfection complexes was added to the cells and the plates were incubated for 4 hours under cell culture conditions. Afterwards, ⅔ of the transfection mixes were replaced with fresh culture medium and the cells were incubated overnight. This transfection method was repeated for the following 2 days. At the third day the transfection complexes were completely replaced with fresh cell culture medium.
  • Medium and cells were analyzed by one day after the last transfection.
    • 7. Expression of the Luciferase Reporter Gene In Vitro
  • The first assessment of the Luciferase expression was performed 5 hours after the transfection and then following every day until the expression declined. For luminescence measurements, representing the Luciferase expression, 20 μL medium was taken from each well 6/24/48/72 hours and 5/10/25 days after transfection, with medium change after each sample taking.
    • 8. Measurement of the Luciferase Activity
  • The activity of the Luciferase enzyme directly after the in vitro translation or 5 hours to 30 days after the transfection of IVT-mRNA into the cells was assessed by adding 100 μL of 2.5 ng/μL substrate coelenterazin to 20 μL cell medium from transfected cells or in vitro translation reaction, respectively. The resulting luminescence of the probes was measured in a microplate reader (Mithras LB 940, Berthold Technologies). FIG. 4 shows the measured luminescence relating to the Luciferase expression in the medium of IVT-mRNA transfected EA.hy926 cells.
  • The results show that even a low amount of 200 ng of IVT Luciferase mRNA can induce a significant Luciferase expression even after a short incubation period of 5 hours. A high expression can be reached with 1 μg of IVT-mRNA up to 24 hours after the transfection, however the following expression course does not differ from the probes with lower amount of IVT-mRNA. Even another increase of the amount of transfected IVT-mRNA up to 2 μg does not result in a higher expression.
    • 9. Detection of (Tropo-)Elastin by Western Blot
  • The proteins from the in vitro translation reactions were separated on a 8% SDS-PAGE and blotted on a nitrocellulose membrane for the immunodetection. The primary antibody was a rabbit polyclonal ELN antibody (central region) from Abgent and the secondary antibody was a goat anti-rabbit IgG (whole molecule) Alkaline Phosphatase Conjugate from Sigma-Aldrich. The elastin protein was revealed by precipitation of the indigo dye resulting from NBT/BCIP reaction with alkaline phosphatase (FIG. 5).
  • The detection of elastin after the in vitro translation made on the basis of IVT-elastin-mRNA confirms the integrity of the mRNA according to the invention. It is understood that a protein detection can only occur when the synthesized protein corresponds to the structures against which the antibody has been developed. For this reason the mRNA according to the invention must have been present in its entirety and functionality for the protein synthesis. Although there is apparently a non specific detection of proteins existing in the in vitro translation mix the specificity of the elastin band is unambiguous since it does not exist in the negative control which only contains the in vitro translation mix without IVT-mRNA.
    • 10. Detection of the Expression of Tropoelastin in the Cell Culture
  • The expression of elastin was analyzed with the Fastin™ Elastin Assay (Biocolor life science assays) according to the manufacturer's instructions. FIG. 6 shows the amount of tropoelastin isolated 24 hours after the last transfection with elastin-IVT-mRNAs, which contained various parts of modified nucleic acids.
  • After a 3-fold transfection of IVT-elastin-mRNA a significant expression of tropoelastin, i.e. of soluble and non cross-linked elastin, could be detected in the cells. It is clear that a particular large amount of 10 μg of transfected IVT-ELN-mRNA has no increasing effect on the elastin expression over only 5 μg. Also the higher amount of modified nucleotides has no positive influence on the expression. Therefore it seems that 5 μg of the IVT-ELN-mRNA with 25% of modified CTP/UTP can cause a sufficient detectable expression of elastin.
  • In another experiment 3×105 cells per well of a 6 well plate were seeded. At the following day the supernatants were aspirated and the cells were washed with 1 ml PBS. Then an incubation took place for 4 hours with Opti-MEM (M), Opti-MEM with Lipofectamine 2000 (M+L), and Opti-MEM with Lipofectamine 2000 and 2.5 μg of elastin-mRNA (100% 5mCTP/ΨFUTP). The cell supernatants were collected after 24 and 48 hours. The supernatants were analyzed by means of dot-blot. The result is shown in FIG. 7. The detection of elastin was made by means of elastin-specific AB. The cells with elastin-mRNA-incubation (M+L+elastin mRNA) show a significantly stronger staining than the cells without mRNA-transfection (M, M+L). The EA.hy926-cells without elastin-mRNA synthesize low amounts of elastin, however by the elastin-mRNA-transfection the elastin synthesis is significantly increased.
    • 11. Assessing the Immunogenicity of the IVT-mRNAs
  • Transfections for the analysis of cytokines and other markers of the immune activation were performed according to the mRNA-transfections described above. Additionally, the immunostimulant polyinosinic/polycytidylic acid (Sigma-Aldrich) was transfected at 100 ng/well as a positive control for cytokine activation. The cells were incubated with the transfection mix under cell culture conditions and the medium was replaced after 3 hours.
  • The following day, cells were lysed and the RNA was extracted with Aurum Total RNA Mini Kit (Biorad). The RNA-concentration was measured and 40 ng of each sample was used for cDNA-synthesis with iScript cDNA-synthesis kit (Biorad). The generated cDNA was used diluted in (qRT)-PCR reactions with the iQ SYBR Green Supermix (Biorad) in triplicates for each sample, combined with a specific primer pair for IFN-∀, IFN-γ, IL-1 B, IL-12, IL-6, IL-8, TNF-α and a GAPDH-specific primer pair. For the quantification of the immune marker expression levels a qRT-PCR was performed in 96-well plates in the CFX Connect Real-Time PCR detection system (Biorad) (FIG. 8). The results show that the in vitro synthesized elastin-mRNA does only cause a very low activation of cytokines in this highly sensitive assay.
    • 12. Coating of Coronary Stents with eGFP-m RNA
  • In another experiment the in vivo expression of eGFP via IVT-mRNA, coated on coronary stents was examined. The in vitro synthesis of the eGFP-mRNA was effected with the plasmid construct pcDNA3.3_eGFP as described in Warren et al. (I.c.). The plasmid was provided by the authors via Addgene (Cambridge, Mass., USA).
  • BMS coronary stents 3×20 mm of Qualimed (Winsen, Germany) were dip-coated, in an emulsion of 70 μg in vitro transcribed eGFP-mRNA complexed with 20 μL of Lipofectamin2000 in nuclease free water and 150 μg of polyactic-co-glycolic acid RESOMER® RG 502 H (Sigma Aldrich) solved in ethyl acetate.
  • The study was performed in accordance with the German animal welfare law and the recommendations on the care and use of laboratory animals postulated by the FELASA (Federation of European Laboratory Animal Science Associations). All protocols and procedures were approved by the Animal Care and Welfare Commission of the University of Tubingen.
  • For this study two female pigs of approx. 65 kg (German land race) supplied by a local “specific pathogen-free” (SPF) breeding facility were used for this study and included in the analysis. After arrival at the animal facility of the University of Tubingen, all animals were allowed one week of adaptation prior to the intervention. During this period clinical examinations were carried out to ensure the health status, especially in consideration of the cardiovascular system.
  • The stents were implanted via a balloon catheter (3 mm) into the left and right coronary arteries of each pig and expanded. The location of the stents was displayed with help of an X-ray apparatus (C-Bogen) and radiopaque material. An overstretching of the arteries was provoqued intentionally. After the implantation, the animals received heparin and clopidogrel to prevent postoperative thromboses.
  • 44 hours after the implantation of the coated stents, the pigs were euthanized. The “stented” vessels were isolated and fixed overnight in 4% formaldehyde.
  • For the fluorescence analysis, the stents were embedded in methylmetacrylate based embedding system Technovit® 9100 from HeraeusKulzer (Wehrheim, Germany), and analyzed by fluorescence intensity decay shape analysis microscopy FIDSAM (fluorescence intensity decay shape analysis microscopy) at the Institute of Analytical Chemistry of the University of Tubingen.
  • The result is shown in FIG. 9. There the part of fluorescent tissue visible after subtraction of the autofluorescence is shown. This fluorescence is only due to the induced eGFP expression and therefore the evidence for efficient uptake and translation of the IVT-mRNA encoding eGFP by cells surrounding the stent material.
    • 13. Pig Skin Model
  • A pig skin model was established to detect the synthesis of the mRNA-induced elastin in the skin. In the first experiments 2.5 μg of Luciferase m RNA/Lipofectamin 2000 complexes were injected into the skin. The skin was chopped after 24 h and for isolating the Luciferase the cells were lysed. The result is shown in FIG. 10. By means of the Luciferase Assay the successful transfection of the cells with Luciferase mRNA was demonstrated.
    • Sequences
  • SEQ ID No. 1: Nucleotide sequence of the IVT-elastin-mRNA (as used in the embodiments)
  • SEQ ID No. 2: Nucleotide sequence of the cDNA, derived from the mRNA of the human elastin, transcript variant 1 (NM_000501.2)
  • SEQ ID No. 3: Nucleotide sequence of the cDNA, derived from the mRNA of the human elastin, transcript variant 2 (NM_001081752.1)
  • SEQ ID No. 4: Nucleotide sequence of the cDNA, derived from the mRNA of the human elastin, transcript variant 3 (NM_001081753.1)
  • SEQ ID No. 5: Nucleotide sequence of the cDNA, derived from the mRNA of the human elastin, transcript variant 4 (NM_001081754.1)
  • SEQ ID No. 6: Nucleotide sequence of the cDNA, derived from the mRNA of the human elastin, transcript variant 5 (NM_001081755.1)
  • SEQ ID No. 7: Amino acid sequence of the elastin isoform a [homo sapiens] (NP_00049.2)
  • SEQ ID No. 8: Amino acid sequence of the elastin isoform b [homo sapiens] (NP_001075221.1)
  • SEQ ID No. 9: Amino acid sequence of the elastin isoform c [homo sapiens] (NP_001075222.1)
  • SEQ ID No. 10: Amino acid sequence of the elastin isoform d [homo sapiens] (NP_001075223.1)
  • SEQ ID No. 11: Amino acid sequence of the elastin isoform e [homo sapiens] (NP_001075224.1)

Claims (18)

What is claimed is:
1. Polyribonucleotide encoding an elastic fibrous protein having a nucleotide sequence comprising at least one said polyribonucleotide stabilizing chemical modification.
2. Polyribonucleotide of claim 1, wherein the elastic fibrous protein is selected from the group consisting of: elastin/tropoelastin, fibrillin, micro-fibrills associated glycoprotein (MAGP), fibuline, elastin-micro-fibrills-interface localized protein (EMILIN), lysyl oxidase (LOX), and precursors thereof.
3. Polyribonucleotide of claim 1 which is an mRNA.
4. Polyribonucleotide of claim 1, wherein the at least one polyribonucleotide stabilizing chemical modification comprises a chemically modified uridine or cytidine.
5. Polyribonucleotide of claim 4, wherein the chemically modified uridine is selected from the group consisting of: pseudouridine, 2-thiouridine, 5-methyluridine, 5-methyluridine-5′-triphosphate (m5U), 5-idouridine-5′-triphosphate (15U), 4-thiouridine-5′-triphosphate (S4U), 5-bromouridine-5′-triphosphate (Br5U), 2′-methyl-2′-deoxyuridine-5′-triphosphate (U2′m), 2′-amino-2′-deoxyuridine-5′-triphosphate (U2′NH2), 2′-azido-2′-deoxyuridine-5′-triphosphate (U2′N3), 2′-fluoro-2′-deoxyuridine-5′-triphosphate (U2′F) and combinations thereof.
6. Polyribonucleotide of claim 4, wherein the chemically modified cytidine is selected from the group consisting of: 5-methylcytidine, 3-methylcytidine, 2-thiocytidine, 2′-methyl-2′-deoxcytidin-5′-triphosphate (C2′m), 2′-amino-2′-deoxycytidine-5′-triphosphate (C2′NH2), 2′-fluoro-2′-deoxycytidine-5′-triphosphate (C2′F), 5-iodcytidine-5′-triphosphate (I5U), 5-bromocytidine-5′-triphosphate (Br5U), 2′-azido-2′-deoxycytidine-5′-triphosphate (C2′N3) and combinations thereof.
7. Polyribonucleotide of claim 1, wherein the chemical modification is selected from the group consisting of: 5 cap structure, preferably a 5′ guanine cap, poly (A) tail, a cap structure analog [anti-reverse cap analog (ARCA; 3′O-Me-m7G(5′)ppp(5′)ppp(5′)G)], a strengthening of the translation-initiation sequence at the start codon AUG by the sequence (CCCCGC)aucGagAUG.
8. Polyribonucleotide of claim 1, comprising a ribonucleotide sequence where at least approx. 25% of the uridines, or where at least approx. 25% of the cytidines are chemically modified.
9. Polyribonucleotide of claim 1, comprising the sequence of SEQ ID No. 1, where at least approx. 25% of the uridines, or where at least approx. 25% of the cytidines are chemically modified.
10. Polyribonucleotide of claim 1, encoding an amino acid sequence selected from the group consisting of: SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, and SEQ ID No. 11.
11. Polyribonucleotide of claim 1, configured for any of the following indications: the induction of the synthesis of an elastic fibrous protein, in age-related loss of elasticity of the skin (wrinkle formation), for promoting the wound healing, for the recovery of the elasticity of vaginal tissue, soft and hard tissue of the periodontium.
12. Polyribonucleotide of claim 1 configured for the treatment of a deficient synthesis of elastic fibrous protein.
13. Polyribonucleotide of claim 1 configured for the treatment of a disease selected from the group consisting of: arteriosclerosis, aortic stenosis, aortic aneurysm, pulmonary emphysema, dermatochalasis, Williams-Beuren syndrome, sub valvular innate aortic stenosis (SVAS).
14. Cosmetic composition, comprising the polyribonucleotide of claim 1 and a cosmetically acceptable formulation.
15. Pharmaceutical composition, comprising the polyribonucleotide of claim 1 and a pharmaceutically acceptable formulation.
16. Medical product comprising the polyribonucleotide of claim 1 or the composition of claim 15.
17. Medical product of claim 16 which is coated with the polyribonucleotide of claim 1 or the composition of claim 15.
18. Medical product of claim 16 which is selected from the group consisting of: medical patch, vascular implant, and stent.
US14/868,259 2013-03-28 2015-09-28 Stabilized polyribonucleotide coding for an elastic fibrous protein Abandoned US20170042782A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US17/494,751 US20220249346A1 (en) 2013-03-28 2021-10-05 Stabilized polyribonucleotide coding for an elastic fibrous protein

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102013005361.7 2013-03-28
DE102013005361.7A DE102013005361A1 (en) 2013-03-28 2013-03-28 polyribonucleotide
PCT/EP2014/056233 WO2014154844A1 (en) 2013-03-28 2014-03-27 Stabilized polyribonucleotide coding for an elastic fibrous protein

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2014/056233 Continuation WO2014154844A1 (en) 2013-03-28 2014-03-27 Stabilized polyribonucleotide coding for an elastic fibrous protein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/494,751 Continuation US20220249346A1 (en) 2013-03-28 2021-10-05 Stabilized polyribonucleotide coding for an elastic fibrous protein

Publications (1)

Publication Number Publication Date
US20170042782A1 true US20170042782A1 (en) 2017-02-16

Family

ID=50442495

Family Applications (2)

Application Number Title Priority Date Filing Date
US14/868,259 Abandoned US20170042782A1 (en) 2013-03-28 2015-09-28 Stabilized polyribonucleotide coding for an elastic fibrous protein
US17/494,751 Pending US20220249346A1 (en) 2013-03-28 2021-10-05 Stabilized polyribonucleotide coding for an elastic fibrous protein

Family Applications After (1)

Application Number Title Priority Date Filing Date
US17/494,751 Pending US20220249346A1 (en) 2013-03-28 2021-10-05 Stabilized polyribonucleotide coding for an elastic fibrous protein

Country Status (6)

Country Link
US (2) US20170042782A1 (en)
EP (1) EP2978402B1 (en)
DE (1) DE102013005361A1 (en)
ES (1) ES2765259T3 (en)
PT (1) PT2978402T (en)
WO (1) WO2014154844A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020180752A1 (en) * 2019-03-01 2020-09-10 Flagship Pioneering Innovations Vi, Llc Polyribonucleotides and cosmetic uses thereof
US11844759B2 (en) 2017-12-15 2023-12-19 Flagship Pioneering Innovations Vi, Llc Compositions comprising circular polyribonucleotides and uses thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4374870A1 (en) 2022-11-22 2024-05-29 Eberhard Karls Universität Tübingen Medizinische Fakultät Codon-optimized oligonucleotide for induction of elastin de-novo synthesis in mammals

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7074596B2 (en) * 2002-03-25 2006-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse mRNA cap analogues
WO2007024708A2 (en) * 2005-08-23 2007-03-01 The Trustees Of The University Of Pennsylvania Rna containing modified nucleosides and methods of use thereof
WO2008067195A2 (en) * 2006-11-17 2008-06-05 Genizon Biosciences Inc. Genemap of the human genes associated with crohn's disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999014346A2 (en) 1997-09-19 1999-03-25 Sequitur, Inc. SENSE mRNA THERAPY
DE102006051516A1 (en) * 2006-10-31 2008-05-08 Curevac Gmbh (Base) modified RNA to increase the expression of a protein
WO2008100789A2 (en) * 2007-02-16 2008-08-21 Benaroya Research Institute At Virginia Mason Compositions and methods for altering elastogenesis
WO2009127230A1 (en) * 2008-04-16 2009-10-22 Curevac Gmbh MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
US20110189292A1 (en) * 2009-04-20 2011-08-04 Allergan, Inc. Dermal fillers comprising silk fibroin hydrogels and uses thereof
BR112012000865A2 (en) * 2009-07-17 2019-09-24 T Tabor Aaron "composition and method for cosmetic genetic modification of substantially intact cells"
AU2010278309B2 (en) 2009-07-31 2013-10-31 Ethris Gmbh RNA with a combination of unmodified and modified nucleotides for protein expression
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
LT3590949T (en) 2010-10-01 2022-07-25 Modernatx, Inc. Ribonucleic acids containing n1-methyl-pseudouracils and uses thereof
JP2014511687A (en) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド Engineered nucleic acid delivery and formulation
EP2710136A4 (en) 2011-05-17 2015-01-21 Moderna Therapeutics Inc Engineered nucleic acids and methods of use thereof for non-human vertebrates

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7074596B2 (en) * 2002-03-25 2006-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse mRNA cap analogues
WO2007024708A2 (en) * 2005-08-23 2007-03-01 The Trustees Of The University Of Pennsylvania Rna containing modified nucleosides and methods of use thereof
WO2008067195A2 (en) * 2006-11-17 2008-06-05 Genizon Biosciences Inc. Genemap of the human genes associated with crohn's disease

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AMA Style Insider. Around, About, Approximately. Downloaded on October 4, 2017 from http://amastyleinsider.com/2012/09/14/around-about-approximately/ *
David Wolman. Natural Healing. (MIT Technology Reviews, Biomedicine, June 21, 2005), pages 1-6, downloaded from https://www.technologyreview.com/s/404312/natural-healing/ on 1/26/2017 *
GenBank Accession No. BC035570, Submitted (31-JUL-2002) National Institutes of Health, Mammalian Gene Collection (MGC), Cancer Genomics Office, National Cancer Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590, USA. *
NCBI - Elastin isoform protein sequence. Downloaded from https://www.ncbi.nlm.nih.gov/protein/126352440 on 4.12.2018. *
Nolte et al. (Mol. Med. 2011 Vol. 17:1213-1222). *
Scientific writing: Difference in meaning of "About," "Around," and "Approximately" by Yateendra Joshi. June 12, 2014. Downloaded from https://www.editage.com/insights/scientific-writing-difference-in-meaning-of-about-around-and-approximately?regid=1507142317 on October 4, 2017. *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11844759B2 (en) 2017-12-15 2023-12-19 Flagship Pioneering Innovations Vi, Llc Compositions comprising circular polyribonucleotides and uses thereof
WO2020180752A1 (en) * 2019-03-01 2020-09-10 Flagship Pioneering Innovations Vi, Llc Polyribonucleotides and cosmetic uses thereof
CN113543766A (en) * 2019-03-01 2021-10-22 旗舰创业创新第六有限责任公司 Polyribonucleotides and their cosmetic use

Also Published As

Publication number Publication date
DE102013005361A1 (en) 2014-10-02
WO2014154844A8 (en) 2014-12-11
ES2765259T3 (en) 2020-06-08
EP2978402B1 (en) 2019-10-16
US20220249346A1 (en) 2022-08-11
WO2014154844A1 (en) 2014-10-02
EP2978402A1 (en) 2016-02-03
PT2978402T (en) 2020-01-14

Similar Documents

Publication Publication Date Title
US20220249346A1 (en) Stabilized polyribonucleotide coding for an elastic fibrous protein
JP7235702B2 (en) Methods and products for nucleic acid production and delivery
CN109803977B (en) Nucleic acid products and methods of administration thereof
JP2022000470A (en) Nucleic acid products and methods of administration thereof
US20180258429A1 (en) Sarna compositions and methods of use
EP3512567B1 (en) Cell-specific expression of modrna
WO2019191341A1 (en) Nucleic acid-based therapeutics
BR122016021558A2 (en) ISOLATED POLYPEPTIDES, THEIR USES, AND PHARMACEUTICAL COMPOSITION
JP2009518022A (en) Anti-myosin VasiRNA and skin decolorization
JP2023145532A (en) Treatment of local skin hypotrophy conditions
JP2021521895A (en) Improved methods for inducing tissue regeneration and senolysis in mammalian cells
EP3679140B1 (en) Stabilized cebpa sarna compositions and methods of use
CN110636854A (en) Prevention and treatment of non-melanoma skin cancer (NMSC)
US20160272967A1 (en) Nucleic acid, pharmaceutical composition and uses thereof
KR20190015153A (en) Pharmaceutical composition for preventing or treating vascular diseases comprising mesenchymal stem cell expressing hepatocyte growth factor
CN114615985A (en) Compositions comprising molecules that modify mRNA and methods of use thereof
EP4374870A1 (en) Codon-optimized oligonucleotide for induction of elastin de-novo synthesis in mammals
KR101527749B1 (en) Compositon for anti-aging of cell comprising miR-186, miR-216b, miR-337-3p and miR-760
WO2023154729A2 (en) Compositions and methods for cardiac tissue regeneration
TW202241459A (en) Use of mirna-485 inhibitors for inducing hair growth
CN117693589A (en) Compositions and methods for modulating gene expression
NZ791466A (en) Nucleic Acid Products And Methods Of Administration Thereof
Dylla et al. 689. Restriction Profiles of Primate TRIM5α on FIV

Legal Events

Date Code Title Description
AS Assignment

Owner name: EBERHARD-KARLS-UNIVERSITAET TUEBINGEN MEDIZINISCHE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WENDEL, HANS-PETER;KELLER, TIMEA;NOLTE, ANDREA;AND OTHERS;SIGNING DATES FROM 20151116 TO 20151127;REEL/FRAME:037730/0169

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION